Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial

Sung Won Lim,Sehhoon Park,Youjin Kim,Jang Ho Cho,Song Ee Park,Hansang Lee,Hee Kyung Kim,Sung Min Kim,Jong Mu Sun,Se-Hoon Lee,Jin Seok Ahn,Keunchil Park,Myung-Ju Ahn

Lung Cancer（2018）

引用 11|浏览17

暂无评分

摘要

•There are no guidelines on who should continue on EGFR TKIs beyond progression.•It showed benefit to continue the TKI with local treatment such as radiotherapy until symptomatic progression.•In patients with pleural metastasis or effusion, continuation of gefitinib beyond progression should be carefully determined.

查看译文

关键词

Gefitinib,Non-small cell lung cancer,EGFR mutation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要